Review Article

Diabetes and Alzheimer Disease, Two Overlapping Pathologies with the Same Background: Oxidative Stress

Sergio Rosales-Corral,1 Dun-Xian Tan,2 Lucien Manchester,2 and Russel J. Reiter2

1Centro de Investigació n Biomédica de Occidente, Instituto Mexicano del Seguro Social, Sierra Mojada 800, Colon ia Independencia, 44340 Guadalajara, JAL, Mexico
2Department of Structural Biology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA

Correspondence should be addressed to Sergio Rosales-Corral; espiral17@gmail.com

Received 11 December 2014; Accepted 10 February 2015

Academic Editor: Angel Catalá

Copyright © 2015 Sergio Rosales-Corral et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

There are several oxidative stress-related pathways interconnecting Alzheimer’s disease and type II diabetes, two public health problems worldwide. Coincidences are so compelling that it is attractive to speculate they are the same disorder. However, some pathological mechanisms as observed in diabetes are not necessarily the same mechanisms related to Alzheimer’s or the only ones related to Alzheimer’s pathology. Oxidative stress is inherent to Alzheimer’s and feeds a vicious cycle with other key pathological features, such as inflammation and Ca2+ dysregulation. Alzheimer’s pathology by itself may lead to insulin resistance in brain, insulin resistance being an intervening variable in the neurodegenerative disorder. Hyperglycemia and insulin resistance from diabetes, overlapping with the Alzheimer’s pathology, aggravate the progression of the neurodegenerative processes, indeed. But the same pathophysiological background is behind the consequences, oxidative stress. We emphasize oxidative stress and its detrimental role in some key regulatory enzymes.

“Diabetes is a disease which often shows itself in families in which insanity prevails.”
Sir Henry Maudsley, The Pathology of Mind, 1879.

1. Introduction

Three hundred forty-seven million people worldwide have diabetes [1], and forty-four million people live with dementia [2].

An inadequate glucose metabolism in the brain resulting from insulin resistance, the reduced ability of insulin to stimulate glucose utilization, is at the center of new therapeutic avenues to treat the most common cause of dementia: Alzheimer’s disease (AD). A recent study showed that over a maximum 11 years of follow-up, diabetic patients experienced a higher incidence of AD than nondiabetic subjects [3]. Moreover, it is postulated that AD represents a neuroendocrine disorder that resembles a unique form of type 2 diabetes mellitus (T2D) accompanied by neurodegeneration, which is sometimes considered type III diabetes [4]. Derived from this hypothesis, some agents that improve insulin sensitivity and reduce hyperinsulinemia have been proposed to aid cognitive functioning for patients with T2D or AD.

Oxidative stress (OxS) plays a major role in T2D [5]. At the same time, all the proposed mechanisms to explain AD pathology have a common factor: OxS. Additionally, there is a well-known connection between the main pathological features of AD, such as amyloid-beta (Aβ) protein and hyperphosphorylated tau, with glucose metabolic intermediates, insulin receptors, and insulin transporters, all in the same context: OxS. In fact, the chemical depletion of insulin and insulin-like growth factor (IGF) signaling mechanisms plus oxidative injury seem to be sufficient to cause AD-type neurodegeneration, as demonstrated in vivo using a model of intracerebral streptozotocin administration [6].
Hyperglycemia and insulin resistance likely have an impact on OxS pathways and neuroinflammatory signals in the brain, thereby connecting diabetes to neurodegeneration. Four pathological-free radical sources in the brain have been described which also feed the OxS in diabetes: mitochondrial dysfunction, inflammation, advanced glycation end products (AGEs), and high cystolic ionic-calcium levels. A particular issue with regard to OxS is the redox-dysregulation, a relevant condition which demands more attention (Figure 1).

It is the purpose of this review on the basis of these observations, to analyze the interrelationships between OxS and redox-regulation in T2D-related pathways and AD pathology.

2. Consuming the Antioxidant Substrates

It has been hypothesized that OxS could be the common pathogenic factor leading to insulin resistance and β-cell dysfunction in T2D [7], as well as the vascular events [8] associated with this global epidemic disease [9]. Reactive oxygen species (ROS) derived from an uncontrolled T2D come mainly from the polyol pathway flux, which consumes the equivalent reducers, essential cofactors for redox systems responsible for scavenging free radicals.

The first enzyme in the polyol pathway, aldose reductase (AR), reduces glucose to sorbitol, which is then transformed to fructose by sorbitol dehydrogenase (SDH) [10]. AR has low substrate affinity for glucose, such that high concentrations of glucose are needed. Hyperglycemia pushes the polyol pathway and AR consumes NADPH to transform glucose into sorbitol. NADPH, nonetheless, is essential for reducing glutathione disulfide (GSSG, the oxidized glutathione) to glutathione (GSH) in a critical reaction to control free radical levels within cells; this is carried out by the enzyme glutathione reductase. The impaired cognitive function associated with hyperglycemia may be corrected by inhibiting the polyol pathway and normalizing sorbitol and taurine in the brain, even without correcting the extracellular hyperglycemia, as demonstrated experimentally in vivo [11].

GSH depletion reduces the capability of cells to remove ROS, making the oxidative processes irreversible [12]. A negative linear correlation between GSSG levels and cognitive status in AD patients has been found [13, 14]. This is such an important correlation that GSH has been considered useful as a biomarker for AD progression [15], and a measurable GSH deficiency is found in T2D [16], as explained below.

GSH is synthesized from glutamate, cysteine, and glycine and diabetic patients have been shown deficient in both cysteine and glycine [17]. It is suggested that such a deficiency is due to a combination of impaired protein turnover and dietary deficiency [17]. Patients with uncontrolled T2D have 74% lower erythrocyte-reduced glutathione concentrations than nondiabetic control subjects, and a higher concentration of erythrocyte-oxidized GSG. Once the GSH synthesis is restored by dietary supplementation with cysteine and glycine, reactive oxygen metabolites and lipid peroxides may be significantly lowered [18].

GSH demand, without replenishment, leads to GSH depletion. The restoration of GSH levels depends on the cysteine into cells via an amino acid antiporter system Xc

−1 to import extracellular l-cystine and export intracellular l-glutamate across the cellular plasma membrane. It is worth remembering that glutamate excitotoxicity is a key protagonist in AD pathogenic [19–21], and the source of glutamate comes precisely from this cystine-glutamate antiporter. In fact, microglia may release glutamate by system Xc

−1 altering glutamate homeostasis, as shown both in oligodendrocytes and in isolated optic nerve fibers [22]. The transportation of cystine into cells, rate limiting for glutathione synthesis and catalyzed by the glutamate cysteine ligase (GCL), as well as the antiporter system Xc

−1 itself, is significantly affected in T2D [23–25], particularly during ketoacidosis [26].

Another important source of NADPH for antioxidant systems comes from the main energy-transducing metabolic systems. A major source of NADPH is the glucose-6-phosphate dehydrogenase (G6PD), which converts glucose to ribose-5-phosphate. During hyperglycemia, G6PD activity decreases significantly; this correlates with low levels of NADPH and reduced glutathione (Figure 2), as observed in kidney cells. The inactivation of G6PD is strongly correlated with phosphorylation of its serine residues by the protein kinase A (PKA) [27]. This cAMP-dependent kinase phosphorylates serine/threonine residues, it is dependent of hyperglycemia, and it is also related to phosphorylation of tau in the AD brain [27, 28]. It is worth mentioning that PKA is a ubiquitous enzyme and its dependence on hyperglycemia is a relevant condition to memory processes in the brain. This is particularly relevant to the AD brain, since PKA is involved in the development of long-term potentiation via cAMP response element-binding protein (CREB) phosphorylation.

In fact, cAMP/PKA/CREB enhancers, such as rolipram and forskolin (PKA activators), have been proposed as useful...
Figure 2: Mitochondria are the main source of free radicals in neurodegenerative diseases, which is particularly true in the Alzheimer brain. The tripeptide GSH is formed in the cytosol from cysteine, glutamate, and glycine as substrates (glutamate reacts with cysteine in the presence of γ-glutamylcysteine ligase to produce γ-glutamylcysteine, which in turn reacts in a second step catalyzed by the enzyme GSH synthetase with glycine, to produce GSH). From the cytosol, GSH is distributed to the nucleus, endoplasmic reticulum (ER), and mitochondria. GSH is a key, abundant antioxidant system to control free radical overproduction in the central nervous system. As long as GSH can be replenished, a reducing intracellular environment prevails, depending on the amount of substrates for its synthesis and the proper functioning of the antiporter system, $\text{Xc}^{-1}$. In T2D, the polyol pathway consumes NADPH to transform glucose into sorbitol, affecting the GSH system. Conversely, the two important substrates for GSH replenishment, cysteine and glycine, are reportedly diminished in T2D. SOD: superoxide dismutase; GR: glutathione reductase; GPx: glutathione peroxidase; GSH: γ-l-glutamyl-l-cysteinyl-glycine; GSSG: oxidized glutathione; NADPH: reduced form of NADP$^+$ nicotinamide adenine dinucleotide phosphate; AR: aldose reductase; SDH: sorbitol dehydrogenase.

Mitochondrial ATP production in T2D is significantly diminished indeed. An evaluation of mitochondrial phosphorylation using proton 1(H) magnetic resonance spectroscopy in muscle of lean, prediabetic insulin resistant subjects, showed that mitochondrial phosphorylation and thus ATP production may be only 30% of controls [35].

A causal relationship between the mitochondrial overproduction of free radicals plus lipid peroxidation and hyperglycemia was shown in vitro with cultured bovine aortic endothelial cells. ROS overproduction exhibited a positive correlation with intracellular AGEs generation, an effect prevented by using antioxidants [36]. Years later in similar experiments, after normalizing mitochondrial superoxide production, AGEs overproduction, protein kinase C (PKC) activation, increased glucose flux through the aldose reductase pathway, and NF-κB activation, were blocked [37].

Another important source of free radicals in AD comes from their rapid release during the respiratory burst, particularly from activated microglia. Again, the AR enzyme from the exacerbated polyol pathway in T2D could be involved, since the transformation of sorbitol to fructose by the enzyme sorbitol dehydrogenase reduces NAD$^+$ to NADH. NADH in turn is essential as a reducing equivalent for the NADPH oxidase, which orchestrates the respiratory burst. Thus, it is feasible to speculate that the polyol pathway may feed the NADPH-oxidase [38]. All of these signs of OxS are key pathogenic events during AD progression [21]; they are actually intrinsic to AD pathology.
Another source of NADPH is the malic enzyme (ME, L-malate: NADP oxidoreductase (decarboxylating)) which catalyzes the reversible formation of pyruvate, CO$_2$, and NADPH from malate and NADP. Malic enzyme has been studied mostly in liver where it supplies reducing equivalents from NADPH for fatty acid biosynthesis. In the brain, cytosolic ME is located in oligodendrocytes where it might deliver NADPH for myelin lipid biosynthesis, whereas in astrocytes it is presumed to participate in the catabolism of excessive Krebs cycle intermediates [39]. Interestingly, the mitochondrial isoform of ME is abundant in neurons, which allows the speculation that it serves as a GSH regeneration system [12]. Interestingly, the mitochondrial isoform of ME is abundant in neurons, which allows the speculation that it serves as a GSH regeneration system [12]. Finally, ME levels are reportedly diminished in T2D, probably linked to a depressed lipogenesis [43] (Figure 3). Thus, after this brief analysis of NADPH sources in brain, it is clear that the high demand of NADPH in T2D, plus a failure to replenish the GSH system, favor OxS, and the progression of AD and/or T2D pathologies (Figure 3).

GSH depletion also induces apoptosis on hippocampal neurons by perturbing calcium (Ca$^{2+}$) homeostasis, as demonstrated in aged mice [31]. Apoptosis and alterations of ionic calcium are intrinsically linked to AD [21].

3. Thioredoxin (Trx)

Working at the expense of NADPH as well, Trx with its active sequence –Cys-Gly-Pro-Cys- is essential to reduce oxidized proteins by cysteine thiol-disulfide exchange. It is abundant in brain, particularly in those regions with high energy demands [44]. Trx reduces peroxidases, methionine sulfoxide reductases, or the ribonucleotide reductase, acting as an electron donor [Trx(SH)$_2$ + ROOH $\rightarrow$ TrxS$_2$ + ROH + H$_2$O]. NADPH further reduces the oxidized Trx. This small oxidoreductase enzyme is essential to maintain the redox status [12].

Activity and availability of Trx, however, can be controlled by alkylating agents such as 4-hydroxynonenal (HNE) which forms thiol adducts, as observed in AD pathology [45]. In T2D, the OxS mediator thioredoxin-interacting protein (TxNIP) plays a key role in Trx inactivation, linking OxS to glucotoxicity. During that process, TxNIP triggers the inflammasome activity as well.

The TxNIP gene appears elevated in insulin resistance/T2D and it is upregulated by glucose [46]. It is implicated as a disease-driver in both pancreatic islets by mediating glucose-induced cell death [47]. In brain, TxNIP is induced in neurons after OxS, chronic hyperglycemic stress, endoplasmic reticulum stress, or ischemia and causes cells to undergo apoptosis [48, 49].

Hyperglycemic signals activate TxNIP through the transcription factor carbohydrate response element-binding protein (ChREBP), which translocates to the nucleus to bind the carbohydrate responsive element (ChoRE) [50] located in the promoter regions of both glycolytic (L-PK) and lipogenic genes (ACC and FAS). Under glucose stimulation, ChREBP uses a tandem ChoRE and CCAAT motifs with the collaboration of the nuclear factor Y (NF-Y) to regulate TxNIP [51].

Impaired insulin signaling in AD brain seems to be related to TxNIP as well. This major intracellular regulator of inflammatory activation and redox stress has been found early overexpressed very early in the brain of the 5XFAD Alzheimer mice model. Thus, TxNIP is also considered a key factor in the insulin resistance and can be induced in astrocytes, endothelial, and neuronal cells in vitro, by adding Aβ to the medium [52].
4. Amplifying the Inflammatory Response

The link between the nucleotide-binding domain, leucine-rich-repeat-containing family, pyrin domain-containing 3 (NLRP3) inflammasome assembly, and TxNIP, readily induced by hyperglycemia, seems to be a transmembrane sensor protein with both kinase and ribonuclease activity known as the inositol-requiring protein-1 alpha (IRE1α). IRE1α is a highly conserved ER sensor and plays a key role during the unfolded protein response in the brain [53]. It is related to Ca\(^{2+}\) homeostasis and cell survival during ER stress [54], this latter process is a relevant phenomenon in the pathogenesis of AD [49, 54–57]. Thus, under ER stress IRE1α becomes active and it is required to promote TxNIP [49]. TxNIP activates the NLRP3 inflammasome and promotes programmed cell death under unremediated ER stress.

Via stimulation of G protein-coupled calcium sensing receptors, extracellular Ca\(^{2+}\) may amplify the inflammatory response activating the NLRP3 inflammasome assembly, as shown in monocytes and macrophages [58]. The process occurs via the inositol/Ca\(^{2+}\) pathway leading to the release of high levels of interleukin 1β and other proinflammatory cytokines, such as IL-1α, IL-6, and TNF. A kinetic curve of proinflammatory cytokines during Aβ-induced OxS in brain shows the same pattern of cytokines as a function of time [59].

TLR (toll-like receptor) is the priming step to activate NF-κB transcription factor, which initiating the NLRP3 multiprotein complex. Stimulation by extracellular ATP may be the second signal to culminate in the complete organization of these large cytosolic complexes of NOD-like receptors, adaptor protein (which is an apoptosis-associated speck-like protein containing a CARD), and caspase-1. In AD brain, the appearance of extracellular ATP, which assumes a role as a damage-associated molecular pattern molecule (DAMP), is linked to bioenergetic dysfunction [60]. NLRP3 culminates in the activation of caspase-1 and releases IL-1β and IL-18, proinflammatory cytokines [58, 61, 62].

NLRP3 induces metabolic inflammation and, importantly, insulin resistance. By deactivating it as happens in obese diabetic patients with a significant loss of weight, insulin resistance diminishes [62]. Furthermore, the elimination of Nlrp3 expression may prevent the activation of caspase-1 as observed linked to obesity and activation of IL-1β and IL-18. Free fatty acids in obese subjects also may induce DAMP, which are linked to the amplification of the innate immune response as occurs in T2D. Free fatty acids also induce insulin-resistance [63] and extracellular ATP [64].

In AD, ATP molecules are also delivered to the extracellular space assuming a new role as DAMP. Thus, extracellular ATP takes part in the innate immune receptor surveillance, as occurs with the amyloid-induced inflammasome [65]. In this manner, extracellular ATP molecules may elicit Ca\(^{2+}\) waves (ATP-dependent glial-transmission) and DAMP-mediated activation of microglia, which in turn activate the phagocytic NADPH-oxidase [66]. This multimorphic membrane-bound enzyme complex links redox control to the neuroinflammatory signaling pathways [67]. Similar actions are observed for the T2D-induced inflammasome.

Hyperglycemia in T2D produces a nonenzymatic glycation and oxidation of proteins and lipids which are known as AGEs. In the AD brain, both AGE and Aβ are abundant and both utilize scavenger receptors (SR) and the receptor for AGE (RAGE). SR and RAGE may define microglia activity [68], but they are also expressed in astrocytes. Also neurons may express RAGE [69]. This calls the attention to the fact that RAGE appears overexpressed in AD brain [70], while RAGE’s activation in vessels may result in amplification and perpetuation of a loop for OxS and dysregulation of proinflammatory cytokines [71].

The key target of these receptors is NF-κB, the transcription factor where the neuroinflammatory pathways converge. RAGE and NF-κB are upregulated during hyperglycemia, as observed in the hippocampus of rat brain [58, 69, 72, 73]. Upregulation of RAGE and NF-κB is accompanied by overactivation of inflammatory factors such as TNF-α, IL-1β, IL-2, and IL-6.

It is important to remember that insulin, acting on its own insulin receptor kinase (IRK), may directly stimulate the NADPH-oxidase pathway, generating an H\(_2\)O\(_2\) burst [74, 75]. Thus, insulin itself may feed OxS, contributing to the vicious cycle of OxS-inflammation.

5. Calcium

The disturbed Ca\(^{2+}\) homeostasis is relevant to AD. Ca\(^{2+}\) is related to acetylcholine expression and its metabolism as well as the activity of its receptor [76]. Ca\(^{2+}\)/calmodulin regulate protein phosphorylation and there are specific calcium-dependent signal transduction pathways in AD neurodegeneration implicating key protein effectors, such as calmodulin-dependent protein kinases (CaMKs), mitogen-activated protein kinases (MAPKs), and CREB. Importantly, Ca\(^{2+}\) waves are a kind of communication between cells in the brain during neuroinflammation which regulate glial cells [21, 65]. Aβ, as part of AD pathology, also enhances the acetylcholinesterase (AchE) activity and induces significant elevations of intracellular Ca\(^{2+}\) by increasing calcium entry through L-type voltage-dependent calcium channels [77–79]. AchE releasing is a Ca\(^{2+}\)-dependent phenomenon [77, 80].

Ca\(^{2+}\) in AD is related to multiple effects: (1) amyloidogenic processing of the amyloid precursor protein (APP) seems to be a Ca\(^{2+}\)-dependent process; (2) Aβ facilitates Ca\(^{2+}\) uptake using a variety of calcium channels; (3) conversely, Ca\(^{2+}\) accelerates Aβ aggregation; (4) the massive entrance of extracellular Ca\(^{2+}\) into cells causes excessive accumulation of Ca\(^{2+}\) within the endoplasmic reticulum and mitochondria; (5) dysregulated intracellular Ca\(^{2+}\) activates a number of enzymes including CaM, which in turn activates CaM-dependent kinases responsible for tau phosphorylation; (6) cytosolic phospholipase-A2 (PLA2) is also a Ca\(^{2+}\)-dependent enzyme which, when activated, causes arachidonic acid release and the subsequent activation of the neuroinflammatory pathway via COX-2. Additionally, the massive influx of Ca\(^{2+}\) promotes proteolytic calpains and neuronal death through the Ca/CaM dependent kinase II and a divergent number of enzymes (reviewed in [21]).
It is feasible to reproduce Ca\textsuperscript{2+} mobilization linked to glutamate exocytosis in T2D [81]. The proposed mechanism is that T2D enhances a K\textsuperscript{-} or 4-AP-evoked Ca\textsuperscript{2+}-dependent glutamate release by increasing the concentration of free cytosolic Ca\textsuperscript{2+} via stimulation of Ca\textsuperscript{2+} entry through both P- and N-type Ca\textsuperscript{2+} channels [81]. In T2D, in addition to the mentioned Ca\textsuperscript{2+} influx into cytosol through P- and N-type Ca\textsuperscript{2+} channels, hyperglycemia also may cause hyperglycosylation of Ca\textsuperscript{2+} channel CaV3.2 and/or membrane lipids that affect channel function causing an increase in current density [82].

The increased cytosolic concentration of Ca\textsuperscript{2+} is related to mitochondrial damage and overproduction of free radicals. Ca\textsuperscript{2+} uptake into mitochondria induces neuritic abnormalities in a dose- and time-dependent manner or the opening of the mitochondrial permeability transition pore coupled to inhibition of respiratory complexes [83]. Another means by which OxS-induced Ca\textsuperscript{2+} may be relevant to both pathologies, AD and T2D, is by amplifying the inflammatory response, a ROS-induced phenomenon where extracellular Ca\textsuperscript{2+} may have a key role, as seen before.

6. Redox Regulation of Key Enzymes

Proinflammatory pathways are redox-regulated processes aided by redox sensors. These thiol-based redox sensors convey information about localized changes in redox potential induced by physiologic or pathologic situations. However, the persistence of OxS keeps progressive pressure on the effective redox reduction potential of these sensors. The NADPH-dependent GSH/GSSG and the thioredoxin system work as redox sensors, but there are thousands of peptidyl-Cys residues that are redox-sensitive and may work as redox sensors, but there are thousands of peptidyl-Cys residues that are redox-sensitive and may work as redox sensors. However, in a study of brain insulin receptors, following the intracerebroventricular injection of streptozotocin, insulin receptor levels were shown to be diminished. The low IRK levels were inversely correlated with the degree of OxS, indicated by malondialdehyde (MDA) and GSH levels. By reducing OxS with melatonin, a powerful antioxidant and free radical scavenger, it was possible to reverse the IRK diminishing [87]. Also, an insulin-independent "basal" insulin receptor kinase activity has been described and is strongly enhanced by H\textsubscript{2}O\textsubscript{2} or by an oxidative shift in the redox status [88].

This redox-regulatory effect on IRK seems to respond to a positive feedback; this is an autoregulatory mechanism, since IRK is capable of inducing H\textsubscript{2}O\textsubscript{2} by activating NADPH-oxidase. However, in opposition to low, regulatory H\textsubscript{2}O\textsubscript{2} levels, OxS inhibits insulin signaling with the consequent inactivation of the Akt/PKB signaling pathway, plus the impairment of GLUT4 translocation, all resulting in insulin resistance [89, 90]. By employing the same redox-regulatory mechanism, H\textsubscript{2}O\textsubscript{2} may also inhibit key components of the IP3/DAG pathway (Inositol 1,4,5-trisphosphate/diacylglycerol), such as the protein tyrosine phosphatase (PTP1B) and the protein phosphatase and tensin homolog (PTEN) [91].

PTP is a negative regulator of insulin and leptin signal transduction, considered a novel target for T2D treatment [92]. IRK phosphorylates the insulin receptor substrate (IRS), which displays binding sites for numerous signaling partners, thereafter a complex set of reactions, orchestrated by phosphatidylinositol-3-kinase (PI3K) connect to the Akt/PKB signaling pathway and PKC. PTEN catalyzes the reverse reaction of PI3K regulating the phosphorylation state of phosphatidylinositol (3,4,5)-trisphosphate (PIP3), a membrane lipid second messenger; PIP3 is therefore a key mediator of the AKT/PKB pathway. These intermediates in turn connect insulin to vital processes such as, mitogenic and stress pathways (IRK → Ras → MAPK → ERK), and metabolic pathways (IRK → PI3K → PDK1 → AKT).

PTP dephosphorylates and inactivates the IRK, reversing the adapter function of the IRS. In fact, the specific PTP-1β has become a prime candidate for therapeutic intervention in diabetes and obesity [74]. These phosphatases have highly conserved cysteine residues within the active site domain, with a low-pKa (4.7 to 5.4), in such a manner that different reactive oxygen species, including H\textsubscript{2}O\textsubscript{2}, oxidize and inactivate the PTP. However, thiol donors, such as GSH, glutaredoxin (Grx), and Trx may rescue thiol groups from irreversible oxidation; via this means the enzyme inactivation can be reversed. Thus, PTP are redox-regulated enzymes [93, 94].

Interestingly, insulin by itself may generate a burst of intracellular H\textsubscript{2}O\textsubscript{2} as a result of its stimulation of the NADPH-oxidase pathway. H\textsubscript{2}O\textsubscript{2}, in turn, induces to a significant reduction in overall PTP activity and enhances the abovementioned insulin cascade. The effect has been shown to be reversed in vitro by suppressing H\textsubscript{2}O\textsubscript{2} with the addition of catalase (2H\textsubscript{2}O\textsubscript{2} → 2H\textsubscript{2}O + O\textsubscript{2}) [75].

Beyond tuning and redox regulation, it is important to highlight that as long as the oxidative pressure increases, the effective redox reduction potential of the redox sensors diminishes. This shifts cell signaling toward proinflammatory pathways, leading to inflammation, apoptosis, and more OxS. Ultimately, a vicious cycle between OxS and neuroinflammation develops [12]. One of the main prooxidant pathways related to hyperglycemia is the PKC signaling pathway; however, the role for this redox sensitive serine/threonine kinase is controversial in AD neurodegeneration.

PKC contains six conserved cysteine and two conserved histidine residues tetrahedrally coordinated by two Zn\textsuperscript{2+} ions into a composite zinc finger [95]. There are variations among the different PKC isoforms related to their responses to OxS; some become active and others become inactive in the same tissue and under a similar context. However, all PKC proteins dissociate from Zn\textsuperscript{2+} after H\textsubscript{2}O\textsubscript{2} treatment [96].
Furthermore, cysteine-rich regions present in the regulatory domain are the sites of phorbol ester/diacylglycerol binding [97] (Figure 4).

PKC can be S-glutathiolated and inactivated during OxS in brain. In an oxidizing microenvironment, disulfide formation due to an oxidative attack dissociates Zn$^{2+}$, which becomes uncoupled [98]. Zn$^{2+}$ is required to maintain the redox homeostasis, and it must be rapidly buffered to reestablish its levels in neurons. By occurring on oxidation within the kinase domain the inactivation of PKC may be reversible, as an adaptive mechanism in response to stress. However, a severe oxidation with disulfide bond formation can be irreversible, leading to protein degradation and apoptosis [99].

PKC has cysteine thiols susceptible to redox-regulation in both the regulatory domains as in the catalytic domain [100] (Figure 4). Examined in tumorigenesis, the oxidation of these thiols may cause an opposite response: oxidation of thiols on the regulatory domain and stimulation of PKC, leading to tumor promotion and cell growth. In contrast, oxidation of thiols in the catalytic domain inhibits PKC activity, interfering with tumor promoters.

In PC12 cells, OxS causes direct redox activation of PKC-$\epsilon$, which in turn leads to a rapid and sustained activation of ERK, necessary and sufficient for neurite outgrowth in these cells [101]. ERK activation in diabetes is linked to diabetic microvascular disease related to the activation of the transcription factor hypoxia inducible factor-1 (HIF-1) [102].

There are many isoforms of PKC and every isoform has some particular mechanisms of regulation and its specific downstream signaling mechanisms [74, 95, 96, 99, 101]. There are classical PKCs ($\alpha$, $\beta$I, $\beta$II, and $\gamma$), novel PKCs ($\delta$, $\eta$, and $\theta$) which depend on DAG alone without the participation of Ca$^{2+}$, and also atypical PKCs ($\zeta$ and $\iota$). The specific roles and the mechanisms of activation or deactivation for each isoform are not completely clarified. This explains, perhaps, some discrepancies about how PKC become involved in certain pathologies.

Hyperglycemia activates different PKC isoforms through OxS or by employing the DAG/IP3 pathway. Additionally, insulin induces superoxide anion via direct stimulation of the NADPH-oxidase, as mentioned above. Superoxide anion is dismutated to H$_2$O$_2$ via SOD and it has been demonstrated that H$_2$O$_2$ directly activates PKC$\gamma$, a classical PKC, acting through the oxidation of the Cys residues within the C1 domain. This may occur independently of elevations in cellular DAG, the natural PKC activator [103]. In the DAG/IP3 pathway, Ca$^{2+}$ from different intracellular sources reacts with DAG to directly activate PKC, while the phospholipase C (PLC) cleaves the phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) into IP3 and DAG. This in turn activates PKC with or without the participation of Ca$^{2+}$, as mentioned before. IP3, in turn, triggers the opening of calcium channels to release Ca$^{2+}$ into the cytosol. Atypical PKCs ($\zeta$ and $\iota$) are independent of Ca$^{2+}$ and DAG. One or several of the abovementioned mechanisms could be involved in AD brain.

Hyperglycemia-induced PKC ($\beta$ and $\delta$ isoforms) have pathogenic consequences (reviewed at [104]) related to (1) activation of proinflammatory pathways through the NF-$\kappa$B transcription factor; (2) blood-flow abnormalities from the overexpression of eNOS and the ET-1 pathway; (3) angiogenesis and vascular permeability derived from VEGF overexpression; (4) capillary occlusion, as a consequence of collagen overproduction and excessive fibronectin due to TGF-$\beta$I signaling; (5) reduced fibrinolysis related to PAI-1 activity; (6) OxS, as a consequence of ROS overproduction led by increased NADPH-oxidase activity.

There is no a consensus, however, about PKC activity in brain during neurodegeneration. In the AD brain, PKC may block the amyloidogenesis by phosphorylating and inactivating the glycogen-synthase kinase-3$\beta$ (GSK-3) which stimulates the amyloidogenic pathway [105]. PKC also promotes the $\alpha$-secretase activity to mediate cleavage of APP, favoring the nonamyloidogenic pathway [106]. As reported elsewhere, by activating the Ca$^{2+}$-dependent $\alpha$ isoform of PKC, the antioxidant melatonin restores neurite formation, microtubule enlargement, and microfilament organization in microspikes and growth cones in cells damaged with H$_2$O$_2$ [107]. A PKC agonist, phorbol 12-myristate 13-acetate, causes cytoskeletal reorganization in the presence of H$_2$O$_2$ in vitro. On the contrary, by using the PKC inhibitor, bisindolylmaleimide, neurite formation, and microfilament reorganization can be blocked [108].

There are additional related to PKC as a neuroprotector; for example, the activation of PKC in brain tissues appears to prevent brain ischemia and is a target for ischemic preconditioning. Once again, the oxidation of PKC$\gamma$ by H$_2$O$_2$ on the C1 domain activates the enzyme causing it to become active and possibly inhibiting gap junctions which provide a protection of cells against OxS [103]. There is an obligatory role for PKC in the induction of brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3), molecular mediators of neuronal growth and homeostatic synapse activity, which are demonstrated decreased in AD brain [109]. By inhibiting in vitro P13K and PKC in N2a cells, it is possible to induce

**Figure 4:** Coordinated Zn bindings with cysteine residues in the catalytic and the regulatory domain of PKC. This figure was generated from pdb entry 1PTQ [95] using the UCSF Chimera package [136].
neuroinflammation [114]. It is worth noting that PKC-β is implicated in vascular alterations, however, as observed in diabetes. In AD also Aβ oligomers, particularly Aβ1–40 and Aβ1–42 peptide content in the hippocampus of 9-month-old Tg 2576 mice, relative to normoglycemic Tg 2576 mice [120]. The effect was attributed to insulin resistance which is responsible for an increased overactivity of the amyloidogenic γ-secretase in addition to reduced activity of IDE. The importance of IDE has been revealed in IDE−/− mice, which accumulate Aβ in brain and become hyperinsulinemia and glucose intolerant [121]. There is a direct interaction of IDE with Aβ for effectively degrading it [122].

Five months of exposure to a high-fat diet resulting in a noninsulin dependent form of diabetes-like insulin resistance was demonstrated to cause a >2-fold elevation in amyloidogenic Aβ1–40 and Aβ1–42 peptide content in the hippocampus of 9-month-old Tg 2576 mice, relative to normoglycemic Tg 2576 mice [120]. The effect was attributed to insulin resistance which is responsible for an increased overactivity of the amyloidogenic γ-secretase in addition to reduced activity of IDE. The importance of IDE has been revealed in IDE−/− mice, which accumulate Aβ in brain and become hyperinsulinemia and glucose intolerant [121]. There is a direct interaction of IDE with Aβ for effectively degrading it [122].

The inhibition of IDE can be an intrinsic phenomena related to AD, since the overproduction of free radicals as observed in this neurodegenerative disorder may affect directly IDE. Oxidizable thiol residues of IDE have been located to the C718, C812, and C819 amino acid residues as reported in a comprehensive mutational analysis of 13 cysteine residues within IDE [123]. This ubiquitous zinc-metalloprotease is a thiol-sensitive enzyme which can be inhibited by nitric oxide, as well as by oxidized glutathione through glutathionylation [124]. H₂O₂ also may interact directly with and deactivate IDE [125]. HNE, a reactive aldehyde, may form an adduct with IDE in order to deactivate it [125]. HNE is a lipid peroxidation derivative and also a powerful alkyllating agent, commonly found in AD brain [21]. The diminished IDE activity, as observed in aged rats [126], is also related to long-chain free fatty acids which exhibit an inhibitory effect on this highly conserved zinc metallopeptidase, as observed in vitro [127]. These facts allow the speculation that OxS is a prerequisite for decreasing IDE activity, as happens in AD and T2D; this facilitates the progression toward memory impairment [128].

Finally, another oxidizable enzyme, important to both of these overlapping degenerative pathologies, T2D and AD, is the glyceraldehyde-3-phosphate dehydrogenase (GAPDH). During T2D, the overproduction of superoxide anion associated with hyperglycemia suppresses the redox-sensitive GAPDH whose primary role in glycolysis is to catalyze the conversion of glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate. GAPDH suppression is a poly (ADP-ribose) polymerase- (PARP-) mediated mechanism [129]. In this manner, the glycolytic pathway is interrupted and deviates toward the hexosamine pathway, PKC activation,
and the AGE pathway. On the other hand, GAPDH has been also linked to neurodegeneration.

Apart from its classical role in glycolysis, new roles for the redox-regulatable GAPDH have been described [130]. A relevant one is in neuronal cell death triggered by oxidative stress. Its translocation to the nucleus is considered an important step in glucose-induced apoptosis, as observed in retinal Muller cells [131]. GAPDH translocates into the nucleus under a variety of stressors, particularly oxidative stress, and it is considered a sensor of nitric oxide (NO) stress [132]. GAPDH has been shown to interact with neurodegenerative disease-associated proteins, including APP [133].

It is under oxidative stress, as observed in neurodegeneration, that oxidative modifications may impart a toxic gain-of-function in GAPDH [134]. GAPDH has several oxidizable cysteines, one of which is located in the catalytic domain where it may undergo oxidation (S-nitrosylation) by NO, and binds to Siah1, an E3 ubiquitin ligase. Thereafter the complex GAPDH-Siah1 translocates to the nucleus where it causes a degradation of Siah1 substrates, which are cytotoxic. [132]. Indeed, S-nitrosylation of GAPDH and \( \alpha 

enolase, another key glycolytic and multifunctional enzyme related to neurodegeneration (its classical role is to catalyze the dehydration of 2-phosphoglycerate to phosphoenolpyruvate), have been found in brains of AD and multiple sclerosis patients [134].

7. Concluding Remarks

Two degenerative mechanisms exist in the same organ, the brain. Both pathological processes produce excessive amounts of free radicals, leading to OxS, which in turn worsens the pathological progression for both AD and T2D. By using the same oxidative stress-dependent mechanisms, diabetes and Alzheimer may feedback on each other, accelerating the neurodegenerative process.

The neurotoxic \( \alpha \beta \) tends to accumulate in brain in line with insulin accumulation. \( \alpha \beta \) by itself contributes to insulin resistance in brain cells which feeds the vicious cycle between OxS and neuroinflammation [21]. It is a cause and consequence of increasing OxS. There are many hypotheses related to the causes of AD, and the cascade of \( \alpha \beta \) is only one of them. Conversely, hyperphosphorylation of tau in AD brain responds to GSK-3, which is identified with insulin resistance in diabetes. Tau may also be phosphorylated by cyclin-dependent protein kinase 5 (cdk5), cAMP-dependent protein kinase (PKA), and stress-activated protein kinases [135]. Tau hyperphosphorylation depends heavily on oxidative stress and \( \text{Ca}^{2+} \) dysregulation, both intrinsic to AD pathogeny [21]. OxS and \( \text{Ca}^{2+} \) dysregulation, the same as neuroinflammation, are dysfunctional mechanisms related to multiple signaling pathways in addition to insulin resistance. But it is important to note that these phenomena feedback on each other, forming a pathological vicious cycle. Oxidative stress is the common factor for AD and T2D. Oxidative stress is a key factor which determines the extent and the progression of damage. T2D and AD might not necessarily be the same pathologies; they do share some insulin resistance-related mechanisms, and they are two pathologies that overlap each other in the same organ, under the same pathogenic background: oxidative stress.

**Abbreviations**

5XFAD: Five times familial Alzheimer's disease mouse model of brain amyloidosis

ACC: Acetyl-CoA carboxylase

AcE: Acetylcholinesterase

AD: Alzheimer's disease

ADDL: \( \alpha \beta \)-derived diffusible ligands

AGEs: Advanced glycation end products

APP: Amyloid precursor protein

AR: Aldose reductase

ATP: Adenosine triphosphate

A\( \beta \): Amyloid beta

B/Akt: Proteinkinase B or Akt

BDNF: Brain-derived neurotrophic factor

CaM: Calmodulin

CaMK: Calmodulin-dependent protein kinase

cAMP: Response element-binding protein

CARD: Caspase activation and recruitment domain

CCAAT motif: Cytidine-cytidine-adenosine-adenosine-thymidine

cdk5: Cyclin-dependent protein kinase 5

ChREBP: Carbohydrate response element binding protein

COX-2: Cyclooxygenase 2, also known as prostaglandin-endoperoxidesynthase 2

CREB: cAMP response element-binding protein

DAG: Diacylglycerol

DAMP: Damage associated molecular pattern molecules

ER: Endoplasmic reticulum

ERK: Extracellular signal-regulated kinase

FAS: Fatty acid synthase

G6PD: Glucose-6-phosphate dehydrogenase

GAPDH: Glyceraldehyde-3-phosphate dehydrogenase

GCL: Glutamate cysteine ligase

Grx: Glutaredoxin

GSH: Glutathione (reduced)

GSK-3: Glycogen synthase kinase 3

GSSG: Glutathione disulfide

HNE: 4-Hydroxynonenal

IDE: Insulin-degrading enzyme

IDH: Isocitrate dehydrogenase

IGF: Insulin-like growth factor

IP3: Inositol 1,4,5-trisphosphate

IRE1\( \alpha \): Inositol-requiring protein-1 alpha

IRK: Insulin receptor kinase

IRS: Insulin receptor substrate

L-PK: L-Pyruvate kinase

MAPK: Mitogen-activated protein kinase

MDA: Malondialdehyde

MRE: Magnetic resonance imaging

NAD\( ^{+} \): Nicotinamide adenine dinucleotide
Conflict of Interests

The authors declare that the review was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interests.

References

[1] World Health Organization, “Diabetes, fact sheet no. 312,” in WHO Media Centre, Fact Sheets, World Health Organization, Ed., vol. 2014, World Health Organization, 2014.

[2] M. Prince, E. Albanese, M. Guerchet, and M. Prina, “Alzheimer’s disease international world Alzheimer report 2014. Dementia and risk reduction,” in Alzheimer’s Disease International World Alzheimer, Alzheimer’s Disease International, Ed., p. 104, Alzheimer’s Disease International, London, UK, 2014.

[3] C. C. Huang, C. M. Chung, H. B. Leu et al., “Diabetes mellitus and the risk of Alzheimer’s disease: a nationwide population-based study,” PLOS ONE, vol. 9, no. 1, Article ID 87095, 2014.

[4] E. Steen, B. M. Terry, E. J. Rivera et al., “Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease—is this type 3 diabetes?” Journal of Alzheimer’s Disease, vol. 7, no. 1, pp. 63–80, 2005.

[5] H. Yang, X. Jin, C. W. K. Lam, and S. K. Yan, “Oxidative stress and diabetes mellitus,” Clinical Chemistry and Laboratory Medicine, vol. 49, no. 11, pp. 1773–1782, 2011.

[6] N. Lester-Coll, E. J. Rivera, S. J. Socia, K. Doiron, J. R. Wands, and S. M. de la Monte, “Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 9, no. 1, pp. 13–33, 2006.

[7] A. Ceriello and E. Motz, “Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 5, pp. 816–823, 2004.

[8] M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications,” Nature, vol. 414, no. 6865, pp. 813–820, 2001.

[9] D. W. Lam and D. LeRoith, “The worldwide diabetes epidemic,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 19, no. 2, pp. 93–96, 2012.

[10] J. H. Kinoshita and C. Nishimura, “The involvement of aldose reductase in diabetic complications,” Diabetes/Metabolism Reviews, vol. 4, no. 4, pp. 323–337, 1988.

[11] J. I. Malone, S. Hanna, S. Saporta et al., “Hyperglycemia not hypoglycemia alters neuronal dendrites and impairs spatial memory,” Pediatric Diabetes, vol. 9, no. 6, pp. 531–539, 2008.

[12] S. Rosales-Corral, R. J. Reiter, D. X. Tan, G. G. Ortiz, and G. Lopez-Armas, “Functional aspects of redox control during neuroinflammation,” Antioxidants and Redox Signaling, vol. 13, no. 2, pp. 193–247, 2010.

[13] D. O. Cristalli, N. Arnal, F. A. Marra, M. J. T. de Alainz, and C. A. Marra, “Peripheral markers in neurodegenerative patients and their first-degree relatives,” Journal of the Neurological Sciences, vol. 314, no. 1-2, pp. 48–56, 2012.

[14] A. McCaddon, P. Hudson, D. Hill et al., “Alzheimer’s disease and total plasma aminothiols,” Biological Psychiatry, vol. 53, no. 3, pp. 254–260, 2003.

[15] S. Saharan and P. K. Mandal, “The emerging role of glutathione in Alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 40, pp. 519–529, 2014.

[16] J. Unger, “Reducing oxidative stress in patients with type 2 diabetes mellitus: a primary care call to action,” Insulin, vol. 3, no. 3, pp. 176–184, 2008.

[17] G. de Luca, P. R. Calpona, A. Caponetti et al., “Amino acid profile in platelets of diabetic patients,” Metabolism: Clinical and Experimental, vol. 50, no. 7, pp. 739–741, 2001.

[18] R. V. Sekhar, S. V. McKay, S. G. Patel et al., “Glutathione synthesis is diminished in patients with uncontrolled diabetes and restored by dietary supplementation with cysteine and glycine,” Diabetes Care, vol. 34, no. 1, pp. 162–167, 2011.

[19] J. T. Greenamyre, W. F. Maragos, R. L. Albin, J. B. Penney, and A. B. Young, “Glutamate transmission and toxicity in Alzheimer’s disease,” Progress in Neuropsychopharmacology and Biological Psychiatry, vol. 12, no. 4, pp. 421–426, 1988.

[20] K. F. S. Bell, D. A. Bennett, and A. C. Cuello, “Paradoxical upregulation of glutamatergic presynaptic boutons during mild cognitive impairment,” The Journal of Neuroscience, vol. 27, no. 40, pp. 10810–10817, 2007.

[21] S. A. Rosales-Corral, D. Acuña-Castroviejo, A. Coto-Montes et al., “Alzheimer’s disease: pathological mechanisms and the beneficial role of melatonin,” Journal of Pineal Research, vol. 52, no. 2, pp. 167–202, 2012.
Oxidative Medicine and Cellular Longevity

[22] M. Domercq, M. V. Sanchez-Gomez, C. Sherwin, E. Etxebarria, R. Fern, and C. Matute, "System xc- and glutamate transporter inhibition mediates microglial toxicity to oligodendrocytes," *The Journal of Immunology*, vol. 178, no. 10, pp. 6549–6556, 2007.

[23] P. Maher, R. Dargusch, J. L. Ehren, S. Okada, K. Sharma, and D. Schubert, "Fisetin lowers methylglyoxal dependent protein glycation and limits the complications of diabetes," *PLoS ONE*, vol. 6, no. 6, Article ID e21226, 2011.

[24] A. Rahigude, P. Bhutada, S. Kaulaskar, M. Aswar, and K. Otari, "Participation of antioxidant and cholinergic system in protective effect of naringenin against type-2 diabetes-induced memory dysfunction in rats," *Neuroscience*, vol. 226, pp. 62–72, 2012.

[25] V. Calabrese, C. Cornelius, V. Leso et al., "Oxidative stress, glutathione status, sirtuin and cellular stress response in type 2 diabetes," *Biochimica et Biophysica Acta: Molecular Basis of Disease*, vol. 1822, no. 5, pp. 729–736, 2012.

[26] M. C. Vantyghem, M. Balduyck, F. Zerimech et al., "Oxidative markers in diabetic ketoacidosis," *Journal of Endocrinological Investigation*, vol. 23, no. 11, pp. 732–736, 2000.

[27] Y. Xu, B. W. Osborne, and R. C. Stanton, "Diabetes causes inhibition of glucose-6-phosphate dehydrogenase via activation of PKA, which contributes to oxidative stress in rat kidney cortex," *The American Journal of Physiology—Renal Physiology*, vol. 289, no. 5, pp. F1040–F1047, 2005.

[28] G. A. Jicha, C. Weaver, E. Lane et al., "cAMP-dependent protein kinase phosphorylations on Tau in Alzheimer’s disease," *The Journal of Neuroscience*, vol. 19, no. 17, pp. 7486–7494, 1999.

[29] Q. Tian, J. X. Zhang, Y. Zhang et al., "Biphasic effects of forskolin on tau phosphorylation and spatial memory in rats," *Journal of Alzheimer’s Disease*, vol. 17, no. 3, pp. 631–642, 2009.

[30] O. V. Vitolo, A. Sant’Angelo, V. Costanzo, F. Battaglia, O. Arancio, and M. Shelanski, "Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 20, pp. 13217–13221, 2002.

[31] I. S. Övey and M. Naziroğlu, "Homocysteine and cytosolic GSH depletion induce apoptosis and oxidative toxicity through cytosolic calcium overload in the hippocampus of aged mice: involvement of TRPM2 and TRPV1 channels," *Neuroscience*, vol. 284, pp. 225–233, 2015.

[32] S. L. Chiu, C. M. Chen, and H. T. Cline, "Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo," *Neuron*, vol. 58, no. 5, pp. 708–719, 2008.

[33] I. S. Kil, J. H. Lee, A. H. Shin, and J. W. Park, "Glycation-induced inactivation of NADP(+)-dependent isocitrate dehydrogenase: Implications for diabetes and aging," *Free Radical Biology and Medicine*, vol. 37, no. 11, pp. 1765–1778, 2004.

[34] S. H. Jo, M. K. Son, H. J. Koh et al., "Control of mitochondrial redox balance and cellular defense against oxidative damage by mitochondrial NADP+-dependent isocitrate dehydrogenase," *The Journal of Biological Chemistry*, vol. 276, no. 19, pp. 16468–16176, 2001.

[35] K. F. Petersen, S. Dufour, D. Befroy, R. Garcia, and G. I. Shulman, "Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes," *The New England Journal of Medicine*, vol. 350, no. 7, pp. 664–671, 2004.

[36] I. Giardino, D. Edelstein, and M. Brownlee, "BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells," *The Journal of Clinical Investigation*, vol. 97, no. 6, pp. 1422–1428, 1996.

[37] T. Nishikawa, D. Edelstein, X. L. Du et al., "Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage," *Nature*, vol. 404, no. 6779, pp. 787–790, 2000.

[38] W. H. Tang, K. A. Martin, and J. Hwa, "Aldose reductase, oxidative stress, and diabetic mellitus," *Frontiers in Pharmacology*, vol. 3, article 87, 2012.

[39] R. Vogel, H. Wiesinger, and B. Hamprecht, "Postnatal development of malic enzyme isoforms in rat brain," in *Neurochemistry*, A. Teelken and J. Korf, Eds., pp. 765–769, Springer, Boston, MA, USA, 1997.

[40] W. O. Nagel, R. T. Dauchy, and L. A. Sauer, "Mitochondrial malic enzymes. An association between NAD(P)+-dependent malic enzyme and cell renewal in Sprague-Dawley rat tissues," *The Journal of Biological Chemistry*, vol. 255, no. 9, pp. 3849–3854, 1980.

[41] G. M. Kurz, H. Wiesinger, and B. Hamprecht, "Purification of cytosolic malic enzyme from bovine brain, generation of monoclonal antibodies, and immunocytochemical localization of the enzyme in glial cells of neural primary cultures," *Journal of Neurochemistry*, vol. 60, no. 4, pp. 1467–1474, 1993.

[42] R. Vogel, B. Hamprecht, and H. Wiesinger, "Malic enzyme isoforms in astrocytes: comparative study on activities in rat brain tissue and astroglia-rich primary cultures," *Neuroscience Letters*, vol. 247, no. 2–3, pp. 123–126, 1998.

[43] F. Belfiore, A. M. Rabuazzo, E. Napoli, V. Borzi, and L. Lo Vecchio, "Enzymes of glucose metabolism and of the citrate cleavage pathway in adipose tissue of normal and diabetic subjects," *Diabetes*, vol. 24, no. 10, pp. 865–873, 1975.

[44] A. Lippoldt, C. A. Padilla, H. Gerst et al., "Localization of thioredoxin in the rat brain and functional implications," *The Journal of Neuroscience*, vol. 15, no. 10, pp. 6747–6756, 1995.

[45] S. S. Hardas, R. Sultana, A. M. Clark et al., "Oxidative modification of lipoic acid by HNE in alzheimer disease brain," *Redox Biology*, vol. 1, no. 1, pp. 80–85, 2013.

[46] A. H. Minn, C. Hafele, and A. Shalev, "Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces beta-cell apoptosis," *Endocrinology*, vol. 146, no. 5, pp. 2397–2405, 2005.

[47] J. Chen, G. Saxena, I. N. Mungrue, A. J. Lusis, and A. Shalev, "Thioredoxin-interacting protein. A critical link between glucose toxicity and β-cell apoptosis," *Diabetes*, vol. 57, no. 4, pp. 938–944, 2008.

[48] G. S. Kim, J. E. Jung, P. Narasimhan, H. Sakata, and P. H. Chan, "Induction of thioredoxin-interacting protein is mediated by oxidative stress, calcium, and glucose after brain injury in mice," *Neurobiology of Disease*, vol. 46, no. 2, pp. 440–449, 2012.

[49] A. G. Lerner, J. P. Upton, P. V. K. Praveen et al., "IRElx induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress," *Cell Metabolism*, vol. 16, no. 2, pp. 250–264, 2012.

[50] M. V. Li, B. Chang, M. Imamura, N. Poungvarin, and L. Chan, "Glucose-dependent transcriptional regulation by an evolutionarily conserved glucose-sensing module," *Diabetes*, vol. 55, no. 5, pp. 1179–1189, 2006.

[51] F.-X. Yu and Y. Luo, "Tandem ChoRE and CCAAT motifs and associated factors regulate txnip expression in response to..."
glucose or adenosine-containing molecules,” PLoS ONE, vol. 4, no. 12, Article ID e8397, 2009.

[52] T. Gouget, M. Djelloul, J. Boucraut et al., “TXNIP, the major player in insulin resistance, is early over-expressed in the brain of the 5XFAD Alzheimer’s mouse model and is induced by Aβ in vitro: emerging role of TXNIP and inflammation in Alzheimer’s Disease progression,” Alzheimer’s & Dementia, vol. 7, no. 4, p. S684, 2011.

[53] J. Dunys, E. Duplan, and F. Checler, “The transcription factor X-box binding protein-1 in neurodegenerative diseases,” Molecular Neurodegeneration, vol. 9, no. 1, article 35, 2014.

[54] S. M. Son, J. Byun, S.-E. Roh, S. J. Kim, and I. Mook-Jung, “Reduced IRE1 mediates apoptotic cell death by disrupting calcium homeostasis via the InsP3 receptor,” Cell Death and Disease, vol. 5, no. 4, Article ID e1888, 2014.

[55] L. Gasparini, G. K. Gouras, R. Wang et al., “Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling,” The Journal of Neuroscience, vol. 21, no. 8, pp. 2561–2570, 2001.

[56] M. T. Gentile, C. Vecchione, A. Maffei et al., “Mechanisms of soluble beta-amyloid impairment of endothelial function,” The Journal of Biological Chemistry, vol. 279, no. 46, pp. 48135–48142, 2004.

[57] A. I. Plácido, C. M. F. Pereira, A. I. Duarte et al., “The role of neuronal nitric oxide synthase in the regulation of beta-amyloid and requires mitogen-activated protein kinases,” Frontiers in Aging Neuroscience, vol. 6, p. 2339, 2012.

[58] S. Rosales-Corral, D. X. Tan, R. J. Reiter, M. Valdivia-Velázquez, J. P. Acosta-Martínez, and G. G. Ortiz, “Kinetics of the neuroinflammation-oxidative stress correlation in rat brain following the injection of fibrillar amyloid-beta into the hippocampus in vivo,” Journal of Neuroimmunology, vol. 150, no. 1-2, pp. 20–28, 2004.

[59] H. M. Wilkins, S. M. Carl, A. C. S. Greenlieb, B. W. Festoff, and R. H. Swerdlow, “Bioenergetic dysfunction and inflammation in Alzheimer’s disease: a possible connection,” Frontiers in Aging Neuroscience, vol. 6, p. 311, 2014.

[60] V. D. Dixin, “Nlrp3 inflammasome activation in type 2 diabetes: is it clinically relevant?” Diabetes, vol. 62, no. 1, pp. 22–24, 2013.

[61] B. Vandanmagsar, Y.-H. Youm, A. Ravussin et al., “The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance,” Nature Medicine, vol. 17, no. 2, pp. 179–189, 2011.

[62] H. Shi, M. V. Kokoeva, K. Inouye, I. Tszameli, H. Yin, and J. S. Flier, “TLR4 links innate immunity and fatty acid-induced insulin resistance,” The Journal of Clinical Investigation, vol. 116, no. 11, pp. 3015–3025, 2006.

[63] S. Mariathasan, D. S. Weiss, K. Newton et al., “Cryopyrin activates the inflammasomes in response to toxins and ATP” Nature, vol. 440, no. 7081, pp. 228–232, 2006.

[64] A. Halle, V. Hornung, G. C. Petzold et al., “The NALP3 inflammasome is involved in the innate immune response to amyloid-beta,” Nature Immunology, vol. 9, no. 8, pp. 857–865, 2008.

[65] C. G. Schipke, C. Boucsein, C. Ohlemeyer, F. Kirchhoff, and H. Kettenmann, “Astrocyte Ca2+ waves trigger responses in microglial cells in brain slices,” The FASEB Journal, vol. 16, no. 2, pp. 255–257, 2002.
[81] E. Satoh and A. Takahashi, “Experimental diabetes enhances Ca\(^{2+}\) mobilization and glutamate exocytosis in cerebral synaptosomes from mice,” *Diabetes Research and Clinical Practice*, vol. 81, no. 2, pp. e14–e17, 2008.

[82] G. M. Keeling, *Determination of the molecular mechanisms of hyperglycemia-induced changes in Cav.3.2 calcium channel properties [M.S. thesis]*, Loyola University Chicago, Chicago, Ill., USA, 2012.

[83] J. K. Parks, T. S. Smith, P. A. Trimmer, J. P. Bennett Jr., and W. J. Davis Parker, “Neurotoxic Abeta peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxide synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro,” *Journal of Neurochemistry*, vol. 76, no. 4, pp. 1050–1056, 2001.

[84] L. I. Leichert, F. Gehrke, H. V. Gudiseva et al., “Quantifying changes in the thiol redox proteome upon oxidative stress in vivo,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 24, pp. 8197–8202, 2008.

[85] L. Frölich, D. Blum-Degen, H.-G. Bernstein et al., “Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease,” *Journal of Neural Transmission*, vol. 105, no. 4-5, pp. 423–438, 1998.

[86] S. M. de la Monte, “Insulin resistance and Alzheimer’s disease;” *BMB Reports*, vol. 42, no. 8, pp. 475–481, 2009.

[87] R. Agraval, E. Tyagi, R. Shukla, and C. Nath, “A study of brain insulin receptors, ACHe activity and oxidative stress in rat model of ICV STZ induced dementia,” *Neuropharmacology*, vol. 56, no. 4, pp. 779–787, 2009.

[88] W. Dröge, “Redox regulation in anabolic and catabolic processes,” *Current Opinion in Clinical Nutrition and Metabolic Care*, vol. 9, no. 3, pp. 190–195, 2006.

[89] L. L. Hansen, Y. Ikeda, G. S. Olsen, A. K. Busch, and L. Mosthaf, “Insulin signaling is inhibited by micromolar concentrations of H\(_2\)O\(_2\). Evidence for a role of H\(_2\)O\(_2\) in tumor necrosis factor alpha-mediated insulin resistance,” *The Journal of Biological Chemistry*, vol. 274, no. 35, pp. 25078–25084, 1999.

[90] A. Tirosk, R. Potashnik, N. Bashan, and A. Rudich, “Oxidative stress disrupts insulin-induced cellular redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase 3-kinase in 3T3-L1 adipocytes. A putative cellular mechanism for impaired protein kinase B activation and GLUT4 translocation,” *The Journal of Biological Chemistry*, vol. 274, no. 15, pp. 10595–10602, 1999.

[91] Z. Cheng, Y. Tseng, and M. F. White, “Insulin signaling meets mitochondria in metabolism,” *Trends in Endocrinology and Metabolism*, vol. 21, no. 10, pp. 589–598, 2010.

[92] T. O. Johnsson, J. Ermolieff, and M. R. Jurasek, “Protein tyrosine phosphatase 1B inhibitors for diabetes,” *Nature Reviews Drug Discovery*, vol. 1, no. 9, pp. 696–709, 2002.

[93] S. G. Rhee, T. S. Chang, Y. S. Bae, S.-R. Lee, and S. W. Kang, “Cellular regulation by hydrogen peroxide,” *Journal of the American Society of Nephrology*, vol. 14, no. 3, pp. S211–S215, 2003.

[94] J. M. Denu and K. G. Tanner, “Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation,” *Biochemistry*, vol. 37, no. 16, pp. 5633–5642, 1998.

[95] G. Zhang, M. G. Kazanietz, P. M. Blumberg, and J. H. Hurley, “Crystal structure of the Cys2 activator-binding domain of protein kinase C\(\delta\) in complex with phorbol ester,” *Cell*, vol. 81, no. 6, pp. 917–924, 1995.

[96] I. Koricheva, “Redox regulation of cardiac protein kinase C,” *Experimental and Clinical Cardiology*, vol. 10, no. 4, pp. 256–261, 2005.

[97] Y. Ono, T. Fujii, K. Igarashi et al., “Phorbol ester binding to protein kinase C requires a cysteine-rich zinc-finger-like sequence,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 86, no. 13, pp. 4868–4871, 1989.

[98] C. Klosmirs, P. A. Karplus, and L. B. Poole, “Cysteine-based redox switches in enzymes,” *Antioxidants & Redox Signaling*, vol. 14, no. 6, pp. 1065–1077, 2011.

[99] S. Barbirz, U. Jakob, and M. O. Glover, “Mass spectrometry unravels disulfide bond formation as the mechanism that activates a molecular chaperone,” *The Journal of Biological Chemistry*, vol. 275, no. 25, pp. 18759–18766, 2000.

[100] R. Gopalakrishna and S. Jaken, “Protein kinase C\(\gamma\) signaling and oxidative stress,” *Free Radical Biology and Medicine*, vol. 28, no. 9, pp. 1349–1361, 2000.

[101] F. Chu, N. E. Ward, and C. A. O’Brien, “Potent inactivation of representative members of each PKC isozyme subfamily and PKD via S-thiolation by the tumor-promotion/progression antagonist glutathione but not by its precursor cysteine,” *Carcinogenesis*, vol. 22, no. 8, pp. 1221–1229, 2001.

[102] C. Treins, S. Giorgetti-Peraldi, J. Murdaca, and E. Van Obberghen, “Regulation of vascular endothelial growth factor expression by advanced glycation end products,” *The Journal of Biological Chemistry*, vol. 276, no. 47, pp. 43836–43841, 2001.

[103] D. Lin and D. J. Takemoto, “Oxidative activation of protein kinase C\(\gamma\)amma through the C1 domain. Effects on gap junctions,” *Journal of Biological Chemistry*, vol. 280, no. 14, pp. 13682–13693, 2005.

[104] S. Hofmann and M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications: a unifying mechanism,” in *Diabetes Mellitus: A Fundamental and Clinical Text*, D. LeRoith, S. I. Taylor, and J. M. Olefsky, Eds., pp. 1441–14457, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 2004.

[105] C. J. Phiel, C. A. Wilson, V. M.-Y. Lee, and P. S. Klein, “GSK-3\(\alpha\) regulates production of Alzheimer’s disease amyloid-\(\beta\) peptides,” *Nature*, vol. 423, no. 6938, pp. 435–439, 2003.

[106] G. Zhu, D. Wang, Y.-H. Lin, T. McMahon, E. H. Koo, and R. O. Messing, “Protein kinase C\(\delta\) suppresses A\(\beta\) production and promotes activation of \(\alpha\)-secretase,” *Biological and Bioophysical Research Communications*, vol. 285, no. 4, pp. 997–1006, 2001.

[107] G. Benitez-King, M. E. Hernández, R. Tovar, and G. Ramírez, “Melatonin activates PKC-\(\alpha\) but not PKC-\(\epsilon\) in N1E-115 cells,” *Neurochemistry International*, vol. 39, no. 2, pp. 95–102, 2001.

[108] G. Benitez-King, L. Ortiz-López, and G. Jiménez-Rubio, “Melatonin precludes cytoskeletal collapse caused by hydrogen peroxide: participation of protein kinase C\(\delta\),” *Therapy*, vol. 2, no. 5, pp. 767–778, 2005.

[109] G. T. Corbett, A. Roy, and K. Pahan, “Sodium phenylbutyrate enhances astrocytic neurotrophin synthesis via protein kinase C (PKC)-mediated activation of cAMP-response element-binding protein (CREB): implications for alzheimer disease therapy,” *The Journal of Biological Chemistry*, vol. 288, no. 12, pp. 8299–8312, 2013.

[110] G.-G. Xu, Y.-Q. Deng, S.-J. Liu, H.-L. Li, and J.-Z. Wang, “Prolonged Alzheimer-like tau hyperphosphorylation induced by simultaneous inhibition of phosphinositrol-3 kinase and protein kinase C in N2a cells,” *Acta Biochimica et Biophysica Sinica*, vol. 37, no. 5, pp. 349–354, 2003.
[111] A. Chauhan, V. P. S. Chauhan, H. Brockerhoff, and H. M. Wisniewski, "Action of amyloid beta-protein on protein kinase C activity," *Life Sciences*, vol. 49, no. 21, pp. 1555–1562, 1991.

[112] R. Etcheberrigaray, M. Tan, I. Dewachter et al., "Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 30, pp. 11141–11146, 2004.

[113] C. Moran, T. G. Phan, J. Chen et al., "Brain atrophy in type 2 diabetes: regional distribution and influence on cognition," *Diabetes Care*, vol. 36, no. 12, pp. 4036–4042, 2013.

[114] D. J. Loegering and M. R. Lenhardt, "Protein kinase C and toll-like receptor signaling," *Enzyme Research*, vol. 2011, no. 1, Article ID 537821, 2011.

[115] A. I. Duarte, P. Santos, C. R. Oliveira, M. S. Santos, and A. C. Rego, "Insulin neuroprotection against oxidative stress is mediated by Akt and GSK-3beta signaling pathways and changes in protein expression," *Biochimica et Biophysica Acta—Molecular Cell Research*, vol. 1783, no. 6, pp. 994–1002, 2008.

[116] J. B. Hoppe, R. L. Frozza, A. P. Horn et al., "Amyloid-beta neurotoxicity in organotypic culture is attenuated by melatonin: involvement of GSK-3beta and neuroinflammation," *Journal of Pinell Research*, vol. 48, no. 3, pp. 230–238, 2010.

[117] H. K. Lee, P. Kumar, Q. Fu, K. M. Rosen, and H. W. Querfurth, "The insulin/Akt signaling pathway is targeted by intracellular beta-amyloid," *Molecular Biology of the Cell*, vol. 20, no. 5, pp. 1533–1544, 2009.

[118] F. G. de Felice, M. N. N. Vieira, T. R. Bomfim et al., "Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of A beta oligomers," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, no. 6, pp. 1971–1976, 2009.

[119] A. M. Moloney, R. J. Griffin, S. Timmons, R. O'Connor, R. Ravid, and C. O'Neill, "Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling," *Neurobiology of Aging*, vol. 31, no. 2, pp. 224–243, 2010.

[120] L. Ho, W. Qin, P. N. Pompil et al., "Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease," *The FASEB Journal*, vol. 18, no. 7, pp. 902–904, 2004.

[121] W. Farris, S. Mansourian, Y. Chang et al., "Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 7, pp. 4162–4167, 2003.

[122] I. V. Kurochkin and S. Goto, "Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme," *FEBS Letters*, vol. 345, no. 1, pp. 33–37, 1994.

[123] M. Neant-Fery, R. D. Garcia-Ordoñez, T. P. Logan et al., "Molecular basis for the thiol sensitivity of insulin-degrading enzyme," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 28, pp. 9582–9587, 2008.

[124] C. M. Cordes, R. G. Bennett, G. L. Siford, and F. G. Hamel, "Redox regulation of insulin degradation by insulin-degrading enzyme," *PLoS ONE*, vol. 6, no. 3, Article ID e18138, 2011.

[125] H. Shinall, E. S. Song, and L. B. Hersh, "Susceptibility of amyloid beta peptide degrading enzymes to oxidative damage: a potential Alzheimer's disease spiral," *Biochemistry*, vol. 44, no. 46, pp. 15345–15350, 2005.

[126] K. Runyan, W. C. Duckworth, A. E. Kitabchi, and G. Huff, "The effect of age on insulin-degrading activity in rat tissue," *Diabetes*, vol. 28, no. 4, pp. 324–325, 1979.

[127] F. G. Hamel, J. L. Upward, and R. G. Bennett, "In vitro inhibition of insulin-degrading enzyme by long-chain fatty acids and their coenzyme A thioesters," *Endocrinology*, vol. 144, no. 6, pp. 2404–2408, 2003.

[128] H. Gutierrez-Hermosillo, D. de Leon-Gonzalez E, R. Palacios-Corona et al., "C allele of the rs2209972 single nucleotide polymorphism of the insulin degrading enzyme gene and Alzheimer's disease in type 2 diabetes, a case control study," *Medicina Clinica*, vol. 144, no. 4, pp. 151–155, 2015.

[129] X. Du, T. Matsumura, D. Edelstein et al., "Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells," *The Journal of Clinical Investigation*, vol. 112, no. 7, pp. 1049–1057, 2003.

[130] A. Colell, D. R. Green, and J.-E. Ricci, "Novel roles for GAPDH in cell death and carcinogenesis," *Cell Death and Differentiation*, vol. 16, no. 12, pp. 1573–1581, 2009.

[131] L. L. Kusner, V. P. Sarthy, and S. Mohr, "Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase: a role in high glucose-induced apoptosis in retinal Müller cells," *Investigative Ophthalmology and Visual Science*, vol. 45, no. 5, pp. 1553–1561, 2004.

[132] M. R. Har a, M. B. Cascio, and A. Sawa, "GAPDH as a sensor of NO stress," *Biochimica et Biophysica Acta: Molecular Basis of Disease*, vol. 1762, no. 5, pp. 502–509, 2006.

[133] D. A. Butterfield, S. S. Hardas, and M. L. B. Lange, "Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Alzheimer's disease: many pathways to neurodegeneration," *Journal of Alzheimer's Disease*, vol. 20, no. 2, pp. 369–393, 2010.

[134] S. F. Newman, R. Sultana, M. Perluigi et al., "An increase in S-glutathionylated proteins in the Alzheimer's disease inferior parietal lobule, a proteomics approach," *Journal of Neuroscience Research*, vol. 85, no. 7, pp. 1506–1514, 2007.

[135] I. Ferrer, T. Gomez-Isla, B. Puig et al., "Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies," *Current Alzheimer Research*, vol. 2, no. 1, pp. 3–18, 2005.

[136] E. F. Pedersen, T. D. Goddard, C. C. Huang et al., "UCSF Chimera—a visualization system for exploratory research and analysis," *Journal of Computational Chemistry*, vol. 25, no. 13, pp. 1605–1612, 2004.